SCHEMBL25754137

SCHEMBL25754137

CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(C(C)(C)C)cc1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CSF1R P07333 1/20 0.35
MAP2K1 Q02750 3/20 0.34
BTK Q06187 2/20 0.34
CDC7 O00311 1/20 0.34
PLK4 O00444 1/20 0.34
AURKA O14965 1/20 0.34
RPS6KA4 O75676 1/20 0.34
CDKL5 O76039 1/20 0.34
STK10 O94804 1/20 0.34
LATS1 O95835 1/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
YES1 P07947 1/20 0.34
LYN P07948 1/20 0.34
RET P07949 1/20 0.34
HCK P08631 1/20 0.34
PDGFRB P09619 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14353015 0.94 MAP2K1 (0.34) MEN1KMT2ACSF1RMAP2K1BTK
SCHEMBL15409478 0.93 MAP2K1 (0.33) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL15409472 0.93 MAP2K1 (0.33) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL25760681 0.91 MAP2K1 (0.37) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL25031703 0.88 RET (0.36) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL25780070 0.88 MAP2K1 (0.38) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL15406959 0.87 MAP2K1 (0.37) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL15423751 0.87 MAP2K1 (0.37) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL15406957 0.87 MAP2K1 (0.37) MEN1KMT2AMAP2K1BTKCDC7
SCHEMBL26907228 0.87 MAP2K1 (0.48) MAP2K1BTKCDC7PLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 MEN1 940/4885KMT2A 1974/4885CSF1R 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.